Analyst firms · Oppenheimer · PRAX

Oppenheimer PRAX price target and rating history

Praxis Precision Medicines Inc. (PRAX) · Health Care

Oppenheimer rates Praxis Precision Medicines Inc. (PRAX) Outperform with a $750 price target, as of its latest action on Dec 15, 2025. It has published 3 rating actions on PRAX since August 2024, including 0 upgrades and 0 downgrades. Across 8 firms with a PRAX price target in the last 12 months, the median target is $474.50. Oppenheimer's $750 is 58% above that.

Current rating
Outperform
Price target
$750
Median target, all firms
$474.50
Actions on PRAX
3

Oppenheimer price target on PRAX

$750$424$9720252026
Oppenheimer price target on PRAX, each point a stated target, August 2024 to December 2025.

Every Oppenheimer rating on PRAX

How other firms rate PRAX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$706Oct 15, 2026
Goldman SachsBuy$447Jul 13, 2026
RBC Capital MarketsOutperform$449Jun 18, 2026
Raymond JamesStrong Buy$815Apr 10, 2026
Wolfe ResearchOutperform$500Feb 24, 2026
Wells FargoEqual Weight$282Feb 2, 2026
OppenheimerOutperform$750Dec 15, 2025
BTIGBuy$424Nov 19, 2025

Questions about Oppenheimer and PRAX

What is Oppenheimer's price target for PRAX?
Oppenheimer's latest stated price target for Praxis Precision Medicines Inc. (PRAX) is $750, from its action on Dec 15, 2025.
What is Oppenheimer's rating on PRAX?
Oppenheimer rates PRAX Outperform, a bullish rating, as of Dec 15, 2025.
When did Oppenheimer last change its view on PRAX?
On Dec 15, 2025, Oppenheimer raises its price target to $750 from $250, keeps Outperform.
How does Oppenheimer's PRAX target compare with other analysts?
Across 8 firms with a PRAX price target in the last 12 months, the median target is $474.50. Oppenheimer's $750 is 58% above that.

All Oppenheimer ratingsPRAX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.